Skip to content
10-K

Annual Report

KALARIS THERAPEUTICS, INC. KLRS

0001193125-26-110659

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 22.93M sh
Shares Diluted FY 2025 · Dec 31, 2025 15.27M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 1.34M sh
Capex FY 2025 · Dec 31, 2025 $200K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$38.37M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$20.67M
Short Term Investments FY 2025 · Dec 31, 2025 $19.93M
Short Term Investments FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $98.05M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $1.64M
Stockholders Equity FY 2025 · Dec 31, 2025 $78.81M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$96.62M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$45.02M
Current Liabilities FY 2025 · Dec 31, 2025 $9.71M
Current Liabilities restated FY 2025 · Dec 31, 2024 $24.7M
Total Liabilities FY 2025 · Dec 31, 2025 $42.92M
Total Liabilities restated FY 2025 · Dec 31, 2024 $56.78M
Current Assets FY 2025 · Dec 31, 2025 $118.81M
Current Assets restated FY 2025 · Dec 31, 2024 $2.61M
Total Assets FY 2025 · Dec 31, 2025 $121.74M
Total Assets restated FY 2025 · Dec 31, 2024 $6.16M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.85
Eps Diluted restated FY 2025 · Dec 31, 2024 −$51.77
Eps Basic FY 2025 · Dec 31, 2025 −$2.85
Eps Basic restated FY 2025 · Dec 31, 2024 −$51.77
Sga Expense FY 2025 · Dec 31, 2025 $15.4M
Sga Expense restated FY 2025 · Dec 31, 2024 $6.69M
Rd Expense FY 2025 · Dec 31, 2025 $30.75M
Rd Expense restated FY 2025 · Dec 31, 2024 $45.04M
Net Income FY 2025 · Dec 31, 2025 −$43.44M
Net Income restated FY 2025 · Dec 31, 2024 −$69.17M
Operating Income FY 2025 · Dec 31, 2025 −$46.15M
Operating Income restated FY 2025 · Dec 31, 2024 −$51.73M